BEAM Description — Beam Therapeutics Inc

Beam Therapeutics is a biotechnology company. Co. has identified four development candidates to date: three from its ex vivo platform, with two candidates targeting hemoglobinopathies and one candidate targeting T-cell leukemia, and one from its in vivo platform targeting glycogen storage disease. BEAM-102 directly corrects the causative mutation in sickle cell disease by recreating a naturally-occurring normal human hemoglobin variant, HbG-Makassar. BEAM-201 is an anti-CD7, multiplex edited, allogeneic chimeric antigen receptor T cell development candidate for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia.

Company Name: 
Beam Therapeutics Inc
Number of ETFs Holding BEAM: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 
 ETF   BEAM Weight   BEAM Amount 
 ARKK   3.89%   $279,007,223         
 ARKG   4.01%   $96,996,017         
 VTI   0.01%   $80,282,446         
 VB   0.06%   $68,826,085         
 IWM   0.14%   $67,463,430         
 XBI   0.94%   $64,456,166         
 VBK   0.15%   $40,805,870         
 VXF   0.04%   $30,568,627         
 IWO   0.27%   $23,764,092         
 XT   0.44%   $12,160,766         
List of all 34 ETFs holding BEAM »
Quotes delayed 20 minutes

Email EnvelopeFree BEAM Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Buy (3.40 out of 4)
45th percentile
(ranked lower than approx. 55% of all stocks covered)
Based on data provided by Zacks Investment Research via

ETFs Holding BEAM | Beam Therapeutics Inc | ETF Channel |

Copyright © 2010 - 2022, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.